Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Prevention and treatment of glucocorticoid-induced osteoporosis.

Literature DB >> 9820881

Prevention and treatment of glucocorticoid-induced osteoporosis.

Abstract

Glucocorticoid-induced osteoporosis is a common clinical problem. This review briefly summarizes the pathogenesis of this disorder. All relevant studies on the prevention and treatment of glucocorticoid-induced osteoporosis are discussed more in detail. As the results of these studies are inconclusive, a proposal for a practical approach of the individual patient is formulated.

Entities: Disease Species

Mesh：

Substances：
Glucocorticoids

Year: 1998 PMID： 9820881 DOI： 10.1023/a:1008654008470

Source DB: PubMed Journal: Pharm World Sci ISSN： 0928-1231

41 in total

1. Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis?

Authors: W F Lems; J W Jacobs; J W Bijlsma; G J van Veen; H H Houben; H C Haanen; M I Gerrits; H J van Rijn
Journal: Ann Rheum Dis Date: 1997-06 Impact factor: 19.103

2. Corticosteroid-induced osteoporosis: effects of a treatment with slow-release sodium fluoride.

Authors: M Greenwald; D Brandli; S Spector; S Silverman; G Golde
Journal: Osteoporos Int Date: 1992-11 Impact factor: 4.507

3. Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients.

Authors: L Montemurro; G Schiraldi; P Fraioli; G Tosi; A Riboldi; G Rizzato
Journal: Calcif Tissue Int Date: 1991-08 Impact factor: 4.333

4. Two-year follow-up of biphosphonate (APD) treatment in steroid osteoporosis.

Authors: I R Reid; S W Heap; A R King; H K Ibbertson
Journal: Lancet Date: 1988-11-12 Impact factor: 79.321

5. Changes in bone mass during low dose corticosteroid treatment in patients with polymyalgia rheumatica: a double blind, prospective comparison between prednisolone and deflazacort.

Authors: M R Krogsgaard; G Thamsborg; B Lund
Journal: Ann Rheum Dis Date: 1996-02 Impact factor: 19.103

6. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin.

Authors: P Sambrook; J Birmingham; P Kelly; S Kempler; T Nguyen; N Pocock; J Eisman
Journal: N Engl J Med Date: 1993-06-17 Impact factor: 91.245

7. Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases.

Authors: T R Dykman; O S Gluck; W A Murphy; T J Hahn; B H Hahn
Journal: Arthritis Rheum Date: 1985-04

8. Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study.

Authors: S J Gallacher; J A Fenner; K Anderson; F M Bryden; S W Banham; F C Logue; R A Cowan; I T Boyle
Journal: Thorax Date: 1992-11 Impact factor: 9.139

9. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.

Authors: J D Adachi; W G Bensen; J Brown; D Hanley; A Hodsman; R Josse; D L Kendler; B Lentle; W Olszynski; L G Ste-Marie; A Tenenhouse; A A Chines
Journal: N Engl J Med Date: 1997-08-07 Impact factor: 91.245

10. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis.

Authors: A Struys; A A Snelder; H Mulder
Journal: Am J Med Date: 1995-09 Impact factor: 4.965

1 in total

Review 1. Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease.

Authors: C J Dunn; K L Goa
Journal: Drugs Date: 2001 Impact factor: 9.546

1 in total